Skip to main content
PTCT
NASDAQ Life Sciences

PTC Q3 Revenue $358M, Full-Year Revenue Guidance Raised to $1.29-$1.32B

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$60
Mkt Cap
$5.386B
52W Low
$58.8
52W High
$90.87
52W Position info
2.0% above low
Off High info
34% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

PTCT is trading near its 52-week low of $58.8 (2.0% above the low).

Summary

PTC reported Q3 2026 revenue of $358 million and raised full-year product revenue guidance to $960-$990 million, while a $111 million ST-920 IPR&D charge pushed the quarter to a $51.7 million net loss.


Key Events · Earnings and Guidance · PTCT

  • Q3 Revenue $358M, Sephience $182M

    Total revenue was $357.8 million versus $211.0 million a year ago; Sephience contributed $181.9 million, up 20% from Q2 2026, with over 2,000 active patients worldwide.

  • Full-Year Guidance Raised

    Total 2026 revenue guidance increased to $1.29-$1.32 billion and product revenue guidance rose to $960-$990 million from $850-$950 million; non-GAAP R&D and SG&A guidance held at $680-$720 million.

  • Net Loss on ST-920 Charge

    Net loss was $51.7 million, or $0.62 per share, including a $111.0 million acquired IPR&D charge for ST-920 and a $19.3 million loss on debt extinguishment.

  • Cash $2.13B, Breakeven Targeted

    Cash, cash equivalents and marketable securities were $2,127.9 million at September 30, 2026, up from $1,945.4 million at December 31, 2025; management reiterated 2026 cash flow breakeven.


Analysis · PTCT · Life Sciences

Revenue of $357.8 million beat the year-ago $211.0 million, powered by Sephience's first full launch year, and management raised full-year product revenue guidance to $960-$990 million from $850-$950 million. The quarter still printed a $51.7 million net loss, driven largely by the $111.0 million upfront ST-920 IPR&D charge and a $19.3 million debt extinguishment loss, so the headline red ink overstates operating deterioration. With $2.13 billion of cash and management reiterating 2026 cash flow breakeven, the raised guidance is the part that matters for the thesis.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PTCT was trading at $60.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $58.80 to $90.87. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PTCT - Latest Insights

PTCT
Nov 03, 2026, 7:00 AM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $61.39
Real-time Price: $63.49 info
Change: +$2.10 (+3%) info
Market Cap: $5.304B info
PTCT
Oct 29, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $62.00
Real-time Price: $63.49 info
Change: +$1.49 (+2%) info
Market Cap: $5.304B info
PTCT
Oct 29, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $64.57
Real-time Price: $63.49 info
Change: -$1.07 (-2%) info
Market Cap: $5.304B info
PTCT
Aug 28, 2026, 5:42 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $70.09
Real-time Price: $63.49 info
Change: -$6.60 (-9%) info
Market Cap: $5.304B info
PTCT
Aug 28, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $70.09
Real-time Price: $63.49 info
Change: -$6.60 (-9%) info
Market Cap: $5.304B info